The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2022
Filed:
Jul. 26, 2018
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Fondation Imagine, Paris, FR;
Université DE Paris, Paris, FR;
Assistance Publique-hôpitaux DE Paris (Aphp), Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Pascale De Lonlay-Debeney, Paris, FR;
Peter Van Endert, Paris, FR;
Marine Madrange, Paris, FR;
Yamina Hamel, Paris, FR;
François-Xavier Mauvais, Paris, FR;
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris, FR;
FOUNDATION IMAGING, Paris, FR;
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
UNIVERSITÉ DE PARIS, Paris, FR;
Abstract
The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).